

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
7 November 2002 (07.11.2002)

PCT

(10) International Publication Number
WO 02/088142 A1

(51) International Patent Classification⁷: **C07D 498/04**, A61K 31/424, A61P 25/00

(21) International Application Number: **PCT/US02/13419**

(22) International Filing Date: 26 April 2002 (26.04.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/286,565 26 April 2001 (26.04.2001) US

(71) Applicant: **WYETH [US/US]**; Five Giralta Farms, Madison, NJ 07940 (US).

(72) Inventors: **STACK, Gary, Paul**; 525 Brookfield Lane, Ambler, PA 19002 (US). **TRAN, Megan**; Apt. 3G, 82 Clinton Street, Hoboken, NJ 07030 (US).

(74) Agents: **BARRETT, Rebecca, R.**; Wyeth, Patent Law Department, Five Giralta Farms, Madison, NJ 07940 et al. (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, JD, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 02/088142 A1

(54) Title: ANTISSCHIZOPHRENIC AMINOMETHYL DERIVATIVES OF 7,8-DIHYDRO-3H-1,6,9-TRIOXA-3-AZA-CYCLOCLOPENTA[a]NAPHTHALEN-2-ONE

(57) Abstract: Compounds of the formula (I) useful for treatment of disorders of the dopaminergic system, such as schizophrenia, schizoaffective disorder, bipolar disorder, Parkinson's disease, L-DOPA induced psychoses and dyskinesias, Tourette's syndrome and hyperprolactinemia and in the treatment of drug addiction such as the addiction to ethanol, nicotine or cocaine and related illnesses.

ANTIPSYCHOTIC AMINOMETHYL DERIVATIVES OF 7,8-DIHYDRO-3H-1,6,9-TRIOXA-3-AZA-CYCLOPENTA[a]NAPHTHALEN-2-ONE

5 This invention relates to antipsychotic aminomethyl derivatives of 7,8-dihydro-3H-1,6,9-trioxa-3-aza-cyclopenta[a]naphthalen-2-one, to processes for preparing them, to methods of using them and to pharmaceutical compositions containing them.

Background of the Invention


10

The clinical treatment of schizophrenia has long been defined by the dopamine hypothesis of schizophrenia, which holds that schizophrenia is a result of hyperactivity of dopaminergic neurotransmission, particularly in limbic brain structures such as nucleus accumbens (the mesolimbic dopamine system). Indeed, the positive symptoms of schizophrenia (hallucinations, delusions, thought disorder) are successfully treated with neuroleptics, which block dopamine receptors. However, such treatment is accompanied by the production of movement disorders or dyskinesias (extrapyramidal side effects), due to the blockade of nigrostriatal dopamine receptors. In addition, neuroleptics do not treat the negative symptoms of schizophrenia (social withdrawal, anhedonia, poverty of speech) which are related to a relative hypoactivity of neurotransmission in the mesocortical dopamine system and which respond to treatment by dopamine agonists.

Efforts to induce antipsychotic activity with dopamine autoreceptor agonists have been successful (Corsini et al., Adv. Biochem. Psychopharmacol. 16, 645-648, 1977; Tamminga et al., Psychiatry 398-402, 1986). Dopamine autoreceptor agonists produce a functional antagonism of dopaminergic neurotransmission by the reduction of neuronal firing and the inhibition of dopamine synthesis and release. Since dopamine autoreceptor agonists are partial agonists at postsynaptic dopamine receptors, they provide a residual level of stimulation sufficient to prevent the production of dyskinesias. Indeed, partial agonists are capable of functioning as either agonists or antagonists depending on the level of dopaminergic stimulation in a given tissue or brain region, and would therefore be expected to have efficacy versus both positive and negative symptoms of schizophrenia. Thus, novel dopamine partial agonists are of great interest for the treatment of schizophrenia and related disorders.

Description of the Invention


In accordance with this invention, there is provided a group of novel
5 antipsychotic agents of the formula:



wherein

10 R^1 is hydrogen, halo, cyano, carboxamido, carboalkoxy of two to six carbon atoms, trifluoromethyl, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, alkanoyloxy of 2 to 6 carbon atoms, amino, mono- or di-alkylamino in which each alkyl group has 1 to 6 carbon atoms, alkanamido of 2 to 6 carbon atoms, or alkanesulfonamido of 1 to 6 carbon atoms;

Z is defined by $N R^2-(CH_2)_n-Y$,



15 Y is hydrogen, hydroxy, cycloalkyl of 3 to 15 carbon atoms or phenyl, substituted phenyl, phenoxy, substituted phenoxy, naphthyl, substituted naphthyl, naphthyoxy, substituted naphthyoxy, heteroaryl, substituted heteroaryl, heteroaryloxy or substituted heteroaryloxy, wherein the heteroaryl or the heteroaryl group of heteroaryloxy is selected from thiophene, furan, pyridine, indole, chroman, coumarin, carbostyryl, and quinoline;

20 R^2 is hydrogen, benzyl or alkyl of 1 to 6 carbon atoms;

n is an integer from 0 to 6;

25 R^3 is hydrogen, alkyl of 1 to 6 carbon atoms, phenyl, substituted phenyl, ω -phenylalkyl, substituted ω -phenylalkyl, ω -diphenylalkyl, substituted ω -diphenylalkyl, wherein the alkyl chain contains 1 to 4 carbon atoms, indole, substituted indole, indazole, substituted indazole, pyridine, substituted

pyridine, pyrimidine, substituted pyrimidine, quinoline, substituted quinoline, benzoisothiazole, substituted benzoisothiazole, benzisoxazole, or substituted benzisoxazole;

5 R⁴ is hydrogen, hydroxy, cyano or carboxamido; ...


5 R⁵ is hydrogen, 1-benzimidazol-2-one, benzoisothiazole, or benzisoxazole, each optionally substituted, or -Q-Ar;

Q is C=O, CHOH, or (CH₂)_m,

m is an integer from 0 to 4;

Ar is phenyl or indole, each optionally substituted; or

10 R⁴ and R⁵, taken together with the carbon atom to which they are attached form



R⁶ is hydrogen; and

15 R⁷ is phenyl, indole, naphthyl, thiophene, benzoisothiazole, or benzisoxazole, each optionally substituted; or

R⁶ and R⁷, taken together with the carbon atoms to which they are attached form phenyl or substituted phenyl;

R⁸ is hydrogen or alkyl of 1 to 6 carbon atoms; and

R⁹, R¹⁰ and R¹¹ are, independently hydrogen, halo, cyano, carboxamido,

20 carboalkoxy of two to six carbon atoms, trifluoromethyl, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, alkanoyloxy of 2 to 6 carbon atoms, amino, mono- or di-alkylamino in which each alkyl group has 1 to 6 carbon atoms, alkanamido of 2 to 6 carbon atoms, or alkanesulfonamido of 1 to 6 carbon atoms; or a pharmaceutically acceptable salt thereof.

25

In some preferred embodiments of the invention R¹ is hydrogen, methoxy or halogen.

In other preferred embodiments of the invention Z is NR²-(CH₂)_n-Y.

R^2 is, in some aspects of the invention, preferably, hydrogen.

R^3 is preferably phenyl, indole, indazole, pyridine, pyrimidine, quinoline, benzoisothiazole, or benzisoxazole each optionally substituted.

In certain preferred embodiments of the invention R^4 is hydrogen or hydroxy.

5 In other preferred embodiments of the invention R^5 is 1-benzimidazol-2-one, benzoisothiazole, benzisoxazole, each optionally substituted, or Q-Ar.


Q is preferably $C=O$ or $(CH_2)_m$.

Preferably R^6 is hydrogen.


10 In other preferred embodiments of the invention R^7 is phenyl, benzoisothiazole, or benzisoxazole, each optionally substituted.

When taken together, R^6 and R^7 preferably form phenyl or substituted phenyl.

In some preferred embodiments of the invention R^1 is hydrogen, methoxy, or halogen, Z is $NR^2-(CH_2)_n-Y$ and R^2 is hydrogen.




15 In other preferred embodiments of the invention, Z is , and R^3 is phenyl, indole, indazole, pyridine, pyrimidine, quinoline, benzoisothiazole, or benzisoxazole, each optionally substituted. More preferably, R^1 is hydrogen,



methoxy or halogen, Z is , and R^3 is phenyl, indole, pyridine, pyrimidine, quinoline, or benzoisothiazole, each optionally substituted:

20 In still other embodiments of the invention, Z is $-N-Cyclohexene-X-R^4$, R^4 is hydrogen or hydroxy and R^5 is 1-benzimidazol-2-one, benzoisothiazole, or benzisoxazole, each optionally substituted. More preferably, R^1 is hydrogen, methoxy


or halogen, Z is $-N-Cyclohexene-X-R^4$, R^4 is hydrogen or hydroxy and R^5 is 1-benzimidazol-2-one, benzoisothiazole, or benzisoxazole




In yet other embodiments of the invention, Z is hydrogen or hydroxy, R⁵ is -Q-Ar, Q is C=O or (CH₂)_m, m is 0 to 4, and Ar is phenyl or indole, each optionally substituted. More preferably, R¹ is hydrogen, methoxy or

halogen, Z is R⁴ is hydrogen or hydroxy, R⁵ is -Q-Ar, Q is C=O, and


5 Ar is phenyl or substituted phenyl.




In other preferred embodiments of the invention Z is hydrogen and R⁷ is phenyl, indole, benzoisothiazole, or benzisoxazole, each optionally substituted. More preferably, R¹ is hydrogen, methoxy or halogen, Z is



10 R⁶ is hydrogen and R⁷ is phenyl, indole, benzoisothiazole, or benzisoxazole, each optionally substituted.



In still other preferred embodiments of the invention Z is and R⁷, taken together with the carbon atoms to which they are attached form phenyl or substituted phenyl. More preferably, R¹ is hydrogen, methoxy or halogen, Z is



15 R⁶ and R⁷, taken together with the carbon atoms to which they are attached form phenyl or substituted phenyl.

Where a substituent is "substituted" as used herein it may include from 1 to 3 substituents the same or different selected from hydrogen, halo, cyano, carboxamido, carboalkoxy of two to six carbon atoms, trifluoromethyl, alkyl of 1 to 6 carbon atoms, 20 alkoxy of 1 to 6 carbon atoms, alkanoyloxy of 2 to 6 carbon atoms, amino, mono- or

di-alkylamino in which each alkyl group has 1 to 6 carbon atoms, alkanamido of 2 to 6 carbon atoms, or alkanesulfonamido of 1 to 6 carbon atoms.

This invention relates to both the R and S stereoisomers of the 8-aminomethyl-
5 7,8-dihydro-3H-1,6,9-trioxa-3-aza-cyclopenta[a]naphthalen-2-ones, as well as to mixtures of the R and S stereoisomers. Throughout this application, the name of the product of this invention, where the absolute configuration of the 8-aminomethyl-7,8-dihydro-3H-1,6,9-trioxa-3-aza-cyclopenta[a]naphthalen-2-one is not indicated, is intended to embrace the individual R and S enantiomers as well as mixtures of the
10 two. In some embodiments of the present invention the S stereoisomer is preferred.

Where a stereoisomer is preferred, it may, in some embodiments be provided substantially free of the corresponding enantiomer. Thus, an enantiomer substantially free of the corresponding enantiomer refers to a compound which is isolated or
15 separated via separation techniques or prepared free of the corresponding enantiomer. Substantially free as used herein means that the compound is made up of a significantly greater proportion of one stereoisomer. In preferred embodiments the compound is made up of at least about 90% by weight of a preferred stereoisomer. In other embodiments of the invention, the compound is made up of at
20 least about 99% by weight of a preferred stereoisomer. Preferred stereoisomers may be isolated from racemic mixtures by any method known to those skilled in the art, including high performance liquid chromatography (HPLC) and the formation and crystallization of chiral salts or prepared by methods described herein. See, for example, Jacques, et al., Enantiomers, Racemates and Resolutions (Wiley
25 Interscience, New York, 1981); Wilen, S.H., et al., Tetrahedron 33:2725 (1977); Eliel, E.L. Stereochemistry of Carbon Compounds (McGraw-Hill, NY, 1962); Wilen, S.H. Tables of Resolving Agents and Optical Resolutions p. 268 (E.L. Eliel, Ed., Univ. of Notre Dame Press, Notre Dame, IN 1972).

30 Alkyl as used herein refers to an aliphatic hydrocarbon chain and includes straight and branched chains such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, n-pentyl, isopentyl, neo-pentyl, n-hexyl, and isohexyl. Lower alkyl refers to alkyl having 1 to 3 carbon atoms.

Alkanamido as used herein refers to the group R-C(=O)-NH- where R is an alkyl group of 1 to 5 carbon atoms.

Alkanoyloxy as used herein refers to the group R-C(=O)-O- where R is an alkyl group of 1 to 5 carbon atoms.

5 Alkanesulfonamido as used herein refers to the group R-S(O)₂-NH- where R is an alkyl group of 1 to 6 carbon atoms.

Alkoxy as used herein refers to the group R-O- where R is an alkyl group of 1 to 6 carbon atoms.

Carboxamido as used herein refers to the group -CO-NH₂.

10 Carboalkoxy as used herein refers to the group R-O-C(=O)- where R is an alkyl group of 1 to 5 carbon atoms.

Cycloalkyl refers to cyclic alkyl groups including mono-, bi- and polycyclic rings having from 3 to 15 carbon atoms. Representative examples include cyclohexyl and adamantlyl.

15 Halogen (or halo) as used herein refers to chlorine, bromine, fluorine and iodine.

Pharmaceutically acceptable salts are those derived from such organic and inorganic acids as: acetic, lactic, citric, cinnamic, tartaric, succinic, fumaric, maleic, malonic, mandelic, malic, oxalic, propionic, hydrochloric, hydrobromic, phosphoric, 20 nitric, sulfuric, glycolic, pyruvic, methanesulfonic, ethanesulfonic, toluenesulfonic, salicylic, benzoic, and similarly known acceptable acids.

Specific compounds of the present invention include:

25 8-aminomethyl-7,8-dihydro-3H-1,6,9-trioxa-3-aza-cyclopenta[a]naphthalen-2-one;

8-(benzylamino-methyl)-7,8-dihydro-3H-1,6,9-trioxa-3-aza-cyclopenta[a]-naphthalen-2-one;

30 8-[(dibenzylamino)-methyl]-7,8-dihydro-3H-1,6,9-trioxa-3-aza-cyclopenta[a]-naphthalen-2-one;


8-[(4-phenyl-butylamino)-methyl]-7,8-dihydro-3H-1,6,9-trioxa-3-aza-cyclopenta[a]-naphthalen-2-one; and

35 8-[4-(1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-ylmethyl]-7,8-dihydro-3H-1,6,9-trioxa-3-aza-cyclopenta[a]naphthalen-2-one, or pharmaceutical salts thereof.

Accordingly in a further aspect this invention provides processes for preparing the compounds of formula (I) which processes comprise one of the following:

a) reacting a compound of formula

5




wherein R¹ is as defined above and X is a leaving group, eg halogen or an organic sulphonyloxy group such as an alkyl- or aryl- sulphonyloxy group, eg -OTs;

10 with a compound of formula (III):




wherein Z is as above to give a compound of formula (I); or

15 b) reacting a compound of formula (IV):



wherein R¹ and R² are defined above; with a compound of formula (III):

20



wherein Y is as defined in Claim 1 and X is a leaving group, e.g. halogen, to give a compound of formula (I); or

25

- c) converting a basic compound of formula (I) to a pharmaceutically acceptable acid addition salt thereof; or
- d) resolving an isomeric mixture of compounds of formula (I) to isolate an enantiomer of a compound of formula (I) or a pharmaceutically acceptable salt thereof, or


5 e) reacting a compound of formula (II) as defined above with an alkali metal azide followed by reduction to give a compound of formula (I) wherein Z is NH₂; or


10 f) alkylating a compound of formula (I) wherein Z is NH₂ with an alkylating agent of formula XR² wherein X is as defined herein and R² is benzyl or alkyl of 1 to 6 carbon atoms to give a corresponding compound of formula (I) wherein Z is NHR².

15 Where necessary in the reactions described herein reactive substituent groups/sites may be protected before the reaction and removed thereafter.

The 8-aminomethyl-7,8-dihydro-3H-1,6,9-trioxa-3-aza-cyclopenta[a]-naphthalen-2-ones of the invention in which Z is NR²-(CH₂)_n-Y are conveniently prepared as illustrated below. Specifically, the appropriately substituted nitroguaiacol is alkylated with allyl bromide in the presence of a suitable base such as sodium hydride and then demethylated by a reagent such as sodium hydroxide. The resulting 4-nitro-2-allyloxyphenol is then alkylated with glycidyl tosylate or an epihalohydrin in the presence of a base such as sodium hydride and heated in a high boiling solvent such as mesitylene or xylene to effect both rearrangement of the allyl group and cyclization of the dioxan ring. The resulting primary alcohol is converted to the tosylate by reaction with p-toluenesulfonyl chloride in the presence of a tertiary amine or pyridine or alternatively to a halide by reaction with carbon tetrabromide or carbon tetrachloride in combination with triphenylphosphine. The allyl side chain is then isomerized by treatment with catalytic bis-acetonitrile palladium (II) chloride in refluxing methylene chloride or benzene and the nitro group reduced to an amine with stannous chloride dihydrate in refluxing ethyl acetate. The amine is then protected with a suitable protecting group such as carbomethoxy or carbobenzoxy via treatment with the appropriate chloroformate and a tertiary base and the olefin is cleaved to the


corresponding aldehyde with sodium periodate and catalytic osmium tetroxide. Oxidation of the aldehyde with meta-chloroperoxybenzoic acid (m-CPBA, a Baeyer-Villiger reaction) and cleavage of the resulting formate ester with methanol over basic alumina gives the phenol, which upon treatment with an excess of carbonyl 5 diimidazole (CDI) cyclizes to give the 8-halo- or 8-tosyloxymethyl-7,8-dihydro-3H-1,6,9-trioxa-3-aza-cyclopenta[a]naphthalen-2-one. Replacement of the halide or tosylate group with azide, followed by





reduction with hydrogen over palladium on carbon gives the primary amine, which is alkylated by treatment with halides or tosylates appropriate to the invention ($\text{Y-(CH}_2\text{n-5-Br, R}^2\text{-Br)}$ in the presence of a tertiary base such as diisopropylethylamine to provide the title compounds of the invention in which Z is $\text{N R}^2\text{-(CH}_2\text{n-Y)}$.

5 The compounds of the invention in which Z is a secondary amine or a cyclic
10 amine may be prepared as illustrated below for examples in which Z is substituted
15 piperazine. The protected o-aminophenol described in the procedure above is first
heated with a secondary amine ($Z\text{-H}$) suitable to the invention in a high-boiling solvent
such as DMSO to replace the tosylate or halide and the resulting intermediate cyclized
via treatment with carbonyl diimidazole as described above to yield the 8-
azaheterocyclimethyl-7,8-dihydro-3H-1,6,9-trioxa-3-aza-cyclopenta[a]-naphthalen-2-
ones of the invention.



The guaiacols, catechols and amines appropriate to the above chemistry are known compounds or can be prepared by one schooled in the art. The compounds of 5 the invention may be resolved into their enantiomers by conventional methods or, preferably, the individual enantiomers may be prepared directly by substitution of (2R)-(-)-glycidyl 3-nitrobenzenesulfonate or tosylate (for the S benzodioxan methanamine) or (2S)-(+)-glycidyl 3-nitrobenzenesulfonate or tosylate (for the R enantiomer) in place of epihalohydrin or racemic glycidyl tosylate in the procedures 10 above.

The antipsychotic activity of the compounds of the invention was established by a determination of functional antagonism of dopamine receptors *in vivo*, specifically the compounds' ability to reduce mouse locomotor activity according to the method of Martin and Bendensky, J. Pharmacol. Exp. Therap. 229: 706-711, 1984, in which mice 15 (male, CF-1, Charles River, 20-30 g) were injected with vehicle or various doses of each drug and locomotor activity was measured for 30 minutes using automated infrared activity monitors (Omnitech - 8 x 8 inch open field) located in a darkened room. ED₅₀'s were calculated from the horizontal activity counts collected from 10 to 20 minutes after dosing using a nonlinear regression analysis with inverse prediction. 20 When examined in this assay, the compounds of this invention, with the exception of example 3, produce ED₅₀'s of less than 50 mg/kg, sc.

Affinity for the dopamine D₂ receptor was established by a modification of the standard experimental test procedure of Seemen and Schaus, European Journal of 25 Pharmacology 203: 105-109, 1991, wherein homogenized rat striatal brain tissue is

incubated with ^3H -quinpirole and various concentrations of test compound, filtered and washed and counted in a Betaplate scintillation counter. The results of this testing with compounds representative of this invention are given below.

5

D₂ Receptor Affinity

10

	<u>Compound</u>	<u>(IC₅₀ (nM))</u>
	Example 1	3.7
	Example 2	0.16
	Example 3	475
10	Example 4	2.0

15

The compounds of the invention are partial agonists at the D₂ sub-family of dopamine receptors. At presynaptic dopamine receptors, the compounds of the invention are autoreceptor agonists; that is, they serve to modulate the synthesis and release of the neurotransmitter dopamine. At postsynaptic dopamine receptors, these compounds are capable of functioning as either agonists or antagonists depending on the level of dopaminergic stimulation. They thus serve to modulate dopaminergic neurotransmission and are thereby useful for treatment of disorders of the dopaminergic system, such as schizophrenia, schizoaffective disorder, bipolar disorder, Parkinson's disease, L-DOPA induced psychoses and dyskinésias, Tourette's syndrome and hyperprolactinemia and in the treatment of drug addiction such as the addiction to ethanol, nicotine or cocaine and related illnesses.

20

Thus the present invention provides methods of treating, preventing, inhibiting or alleviating each of the maladies listed above in a mammal, preferably in a human, the methods comprising providing a pharmaceutically effective amount of a compound of this invention to the mammal in need thereof.

25

Also encompassed by the present invention are pharmaceutical compositions for treating or controlling disease states or conditions of the central nervous system comprising at least one compound of Formula I, mixtures thereof, and/or pharmaceutical salts thereof, and a pharmaceutically acceptable carrier therefore. Such compositions are prepared in accordance with acceptable pharmaceutical procedures, such as described in *Remingtons Pharmaceutical Sciences*, 17th edition,

ed. Alfonoso R. Gennaro, Mack Publishing Company, Easton, PA (1985). Pharmaceutically acceptable carriers are those that are compatible with the other ingredients in the formulation and biologically acceptable.

5 The compounds of this invention may be administered orally or parenterally, neat or in combination with conventional pharmaceutical carriers. Applicable solid carriers can include one or more substances which may also act as flavoring agents, lubricants, solubilizers, suspending agents, fillers, glidants, compression aids, binders or tablet-disintegrating agents or an encapsulating material. In powders, the carrier is
10 a finely divided solid which is in admixture with the finely divided active ingredient. In tablets, the active ingredient is mixed with a carrier having the necessary compression properties in suitable proportions and compacted in the shape and size desired. The powders and tablets preferably contain up to 99% of the active ingredient. Suitable solid carriers include, for example, calcium phosphate, magnesium stearate, talc,
15 sugars, lactose, dextrin, starch, gelatin, cellulose, methyl cellulose, sodium carboxymethyl cellulose, polyvinylpyrrolidine, low melting waxes and ion exchange resins.

20 Liquid carriers may be used in preparing solutions, suspensions, emulsions, syrups and elixirs. The active ingredient of this invention can be dissolved or suspended in a pharmaceutically acceptable liquid carrier such as water, an organic solvent, a mixture of both or pharmaceutically acceptable oils or fat. The liquid carrier can contain other suitable pharmaceutical additives such as solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavoring agents, suspending agents, thickening
25 agents, colors, viscosity regulators, stabilizers or osmo-regulators. Suitable examples of liquid carriers for oral and parenteral administration include water (particularly containing additives as above e.g. cellulose derivatives, preferably sodium carboxymethyl cellulose solution), alcohols (including monohydric alcohols and polyhydric alcohols e.g. glycols) and their derivatives, and oils (e.g. fractionated
30 coconut oil and arachis oil). For parenteral administration the carrier can also be an oily ester such as ethyl oleate and isopropyl myristate. Sterile liquid carriers are used in sterile liquid form compositions for parenteral administration.

Liquid pharmaceutical compositions which are sterile solutions or suspensions can be utilized by, for example, intramuscular, intraperitoneal or subcutaneous injection. Sterile solutions can also be administered intravenously. Oral administration may be either liquid or solid composition form.

5

Preferably the pharmaceutical composition is in unit dosage form, e.g. as tablets, capsules, powders, solutions, suspensions, emulsions, granules, or suppositories. In such form, the composition is sub-divided in unit dose containing appropriate quantities of the active ingredient; the unit dosage forms can be packaged

10 compositions, for example packeted powders, vials, ampoules, prefilled syringes or sachets containing liquids. The unit dosage form can be, for example, a capsule or tablet itself, or it can be the appropriate number of any such compositions in package form.

15 The amount provided to a patient will vary depending upon what is being administered, the purpose of the administration, such as prophylaxis or therapy, and the state of the patient, the manner of administration, and the like. In therapeutic applications, compounds of the present invention are provided to a patient already suffering from a disease in an amount sufficient to cure or at least partially ameliorate
20 the symptoms of the disease and its complications. An amount adequate to accomplish this is defined as a "therapeutically effective amount." The dosage to be used in the treatment of a specific case must be subjectively determined by the attending physician. The variables involved include the specific condition and the size, age and response pattern of the patient. Generally, a starting dose is about 10
25 mg per day with gradual increase in the daily dose to about 200 mg per day, to provide the desired dosage level in the human.

Provide, as used herein, means either directly administering a compound or composition of the present invention, or administering a prodrug, derivative or analog
30 which will form an equivalent amount of the active compound or substance within the body.

The present invention includes prodrugs of compounds of Formula I. "Prodrug", as used herein means a compound which is convertible *in vivo* by metabolic means

(e.g. by hydrolysis) to a compound of Formula I. Various forms of prodrugs are known in the art, for example, as discussed in Bundgaard, (ed.), Design of Prodrugs, Elsevier (1985); Widder, et al. (ed.), Methods in Enzymology, vol. 4, Academic Press (1985); Krogsgaard-Larsen, et al., (ed). "Design and Application of Prodrugs,
5 Textbook of Drug Design and Development, Chapter 5, 113-191 (1991), Bundgaard, et al., Journal of Drug Deliver Reviews, 8:1-38(1992), Bundgaard, J. of Pharmaceutical Sciences, 77:285 et seq. (1988); and Higuchi and Stella (eds.)
Prodrugs as Novel Drug Delivery Systems, American Chemical Society (1975).

10 The following examples illustrate the production of representative compounds of this invention.

INTERMEDIATE 1

3-Allyloxy-4-methoxynitrobenzene

15 97.5 g (0.51 mole) of the sodium salt of 5-nitroguaia col was dissolved in one liter of DMF and 1.5 equivalents of allyl bromide added. The reaction was heated to 65°C for two hours, after which time much of the dark color had discharged and tlc (1:1 CH₂Cl₂/hexane) indicated loss of starting material. The solvent was concentrated
20 in vacuum and the residue washed with water. The product was isolated by filtration and dried in a vacuum. This gave 112 g of pale yellow solid. A sample recrystallized from methanol, gave m.p. 93-94°C.

INTERMEDIATE 2

2-Allyloxy-4-nitrophenol

To one liter of dimethyl sulfoxide was added 750 mL of 2 N aqueous sodium hydroxide and the mixture was heated to 65°C. The pale yellow solid 3-allyloxy-4-methoxynitrobenzene prepared above was added in portions over a 30 minute period
30 and then the temperature was raised to 95°C and maintained for 3 hours, after which time the starting material had been consumed. The mixture was allowed to cool and poured into a mixture of 1 L ice and 1 L 2 N HCl. 73 Grams of crude but homogeneous (by tlc 1:1 CH₂Cl₂/hexane) desired product was isolated as a light brown solid by filtration. This material was subsequently dissolved in 1:1

hexane/methylene chloride and filtered through silica gel to give 68 g of pale yellow solid, which, when recrystallized from ethylacetate/hexane, gave m.p. 61-62°C. The aqueous mother liquors from the initial crystallization above were extracted with 2 L of ethyl acetate. This was dried over sodium sulfate, filtered and evaporated to a dark
5 oil. Column chromatography on silica with 1:1 CH₂Cl₂/hexane gave an additional 12 g of the title compound as a yellow solid. Elution with 2% MeOH in CHCl₃ gave 12 g of a dark oil which slowly crystallized in vacuum. This proved to be the Claisen product, 3-allyl-4-nitrocatechol.

10

INTERMEDIATE 32-(2-Allyloxy-4-nitrophenoxyethyl)-oxirane

20 g (0.50 mole) of 60% NaH/mineral oil was placed in a two liter flask and washed with 500 mL of hexane. 1 L of DMF was added, followed by 77 g (0.40 mole)
15 of the 2-allyloxy-4-nitrophenol prepared in the previous step. Addition of the phenol was performed in portions under argon. After stirring the mixture for 30 minutes at room temperature under argon, 108 g (0.48 moles) of (R)-glycidyl tosylate was added and the mixture heated at 70-75°C under nitrogen overnight. Upon cooling, the DMF was removed in vacuum and replaced with one liter of methylene chloride. This was
20 washed with 500 mL portions of 2 N HCl, saturated sodium bicarbonate and saturated brine and dried over sodium sulfate. The mixture was filtered, concentrated to an oil in vacuum and column chromatographed on silica gel using 1:1 hexane/methylene chloride as eluant. This gave 43 g of product contaminated with traces of the two starting materials, followed by 21 g of pure product as a pale yellow solid. The impure
25 material was recrystallized from 1.2 L of 10% ethyl acetate/hexane to give 34 g of pure (homogeneous on silica gel tlc with 1:1 hexane/methylene chloride) (R)-2-(2-allyloxy-4-nitrophenoxyethyl)-oxirane (m.p. 64°C).

Elemental Analysis for: C₁₂H₁₃NO₅

Calc'd: C, 57.37; H, 5.21; N, 5.58

30 Found: C, 57.50; H, 5.21; N, 5.43

INTERMEDIATE 4(8-Allyl-7-nitro-2,3-dihydro-benzo(1,4)dioxin-2-yl)-methanol

(R)-2-(2-Allyloxy-4-nitrophenoxyethyl)-oxirane (20 g, 80 mmoles) prepared
5 as above was heated at 145-155°C in mesitylene for 24 hours under nitrogen.
Filtration of the black solid which formed gave 1.5 g of very polar material.
Evaporation of the solvent in vacuum followed by column chromatography on silica gel
with methylene chloride as eluant gave 10 g of recovered starting material and 7.5 g
of the desired rearranged (S)-(8-allyl-7-nitro-2,3-dihydro-benzo(1,4)dioxin-2-yl)-
10 methanol, which slowly crystallized on standing in vacuum (m.p. 67°C). The yield
based on recovered starting material is 75%.

Elemental Analysis for: C₁₂H₁₃NO₅

Calc'd: C, 57.37; H, 5.21; N, 5.58

Found: C, 57.26; H, 5.20; N, 5.35

15

INTERMEDIATE 5Toluene-4-sulfonic acid 8-allyl-7-nitro-2,3-dihydro-
benzo(1,4)dioxin-2-ylmethyl ester

20 9.55 g (38.0 mmole) of (S)-(8-allyl-7-nitro-2,3-dihydro-benzo(1,4)dioxin-2-yl)-
methanol was dissolved in 465 mL of pyridine, 29.0 g (152 mmole) of p-
toluenesulfonyl chloride was added and the mixture stirred at room temperature under
nitrogen overnight. Water was then added to quench the excess tosyl chloride and
the solvent was removed in vacuum and replaced with methylene chloride. This
25 solution was washed with 2 N HCl, with saturated sodium bicarbonate, and with
saturated brine, and dried over magnesium sulfate. Filtration, evaporation in vacuum
and column chromatography on silica gel with 1:1 hexane/methylene chloride as
eluant gave 12.6 g (92%) of toluene-4-sulfonic acid (R)-allyl-7-nitro-2,3-
benzo(1,4)dioxin-2-ylmethyl ester, which slowly crystallized to a tan solid (m.p. 60-
30 62°C) upon standing.

Elemental Analysis for: C₁₉H₁₉NO₇S

Calc'd: C, 56.29; H, 4.72; N, 3.45

Found: C, 56.13; H, 4.58; N, 3.44

INTERMEDIATE 6{7-Nitro-8-[1-propenyl]-2,3-dihydro-1,4-benzodioxin-2-yl}methyl
4-methylbenzenesulfonate

5

To a solution of 10.0 g (24.0 mmole) of (R)-[8-allyl-7-nitro-2,3-dihydro-1,4-benzodioxin-2-yl]methyl 4-methylbenzenesulfonate in 700 mL of benzene was added 1.03 g of bis(acetonitrile)dichloropalladium (II) and the mixture was refluxed under nitrogen for 48 hours. The catalyst was then removed by filtration and the filtrate 10 concentrated in vacuum to a brown oil. Column chromatography on silica gel with methylene chloride as eluant gave 7.2 g of the title compound as a mixture of E and Z isomers. A sample of {(2R)-7-nitro-8[(E)-1-propenyl]-2,3-dihydro-1,4-benzodioxin-2-yl}methyl 4-methylbenzenesulfonate was obtained as a yellow solid (m.p. 105-106 °C) by evaporation of a pure E isomer-containing fraction.

15 Elemental Analysis for: C₁₉H₁₉NO₇SCalc'd: C, 56.29; H, 4.72; N, 3.45Found: C, 56.12; H, 4.64; N, 3.39INTERMEDIATE 720 {7-Amino-8-[1-propenyl]-2,3-dihydro-1,4-benzodioxin-2-yl}methyl
4-methylbenzenesulfonate

10.0 g (24.0 mmole) of {(2R)-7-nitro-8-[1-propenyl]-2,3-dihydro-1,4-benzodioxin-2-yl}methyl 4-methylbenzenesulfonate and 28.0 g (123 mmole) of stannous 25 chloride dihydrate were combined and heated to 70°C in ethyl acetate (250 mL) for 6 hours under nitrogen. After cooling to room temperature, the reaction mixture was poured into ice and was made basic with sodium bicarbonate. It was then extracted with ethyl acetate, washed with brine, dried over magnesium sulfate, filtered and evaporated to a brown oil. The crude oil was then chromatographed on silica gel with 30 50% hexane/methylene chloride to remove impurities and the desired product was eluted with 0.5% methanol/CH₂Cl₂ to give 8.16 g (91%) of the (R)-enantiomer of the title compound as a yellow oil. For analytical purposes, 50 mg of the yellow oil was crystallized from ethanol with the addition of fumaric acid to give the fumarate of the title compound. MS (ESI) m/z 375 (M+H)⁺.

Elemental Analysis for: C₁₉H₂₁NO₅S • 1.00 C₄H₄O₄

Calc'd: C, 56.20; H, 5.13; N, 2.85

Found: C, 56.40; H, 4.99; N, 2.91

5

INTERMEDIATE 8

{7-[(Methoxycarbonyl)amino]-8-[1-propenyl]-2,3-dihydro-1,4-benzodioxin-2-yl}methyl 4-methylbenzenesulfonate

Methyl chloroformate (2.93 mL, 37.9 mmole) was added to a solution of {(2R)-7-amino-8-[1-propenyl]-2,3-dihydro-1,4-benzodioxin-2-yl}methyl 4-methyl-benzene-sulfonate (2.35 g, 6.30 mmole) in ethyl acetate (125 mL), followed by the addition of N,N-diisopropylethylamine (5.50 mL, 31.6 mmole) dropwise over a period of 20 minutes. The solution was stirred under nitrogen at room temperature over a period of 10 hours. This solution was then washed with 2N aqueous HCl, saturated aqueous sodium bicarbonate and brine and dried over magnesium sulfate. Filtration, evaporation in vacuum and column chromatography on silica gel with 0.2% methanol/methylene chloride gave the (R)-enantiomer of the title compound as a white foam (1.90 g, 70%). ¹H (CDCl₃) doublet, 7.8 δ (2 H); doublet, 7.3 δ (3 H); doublet, 6.7 δ (1 H); broad singlet, 6.6 δ (1 H); multiplet, 6.1 δ (2 H); multiplet, 4.4 δ (1 H); multiplet 4.2 δ (3 H); multiplet, 4.0 δ (1 H); singlet, 3.7 δ (3 H); singlet, 2.4 δ (3 H); doublet, 1.9 δ (3 H).

INTERMEDIATE 9

{8-Formyl-7-[(methoxycarbonyl)amino]-2,3-dihydro-1,4-benzodioxin-2-yl}methyl 4-methylbenzenesulfonate

To a solution of {(2R)-7-[(methoxycarbonyl)amino]-8-[1-propenyl]-2,3-dihydro-1,4-benzodioxin-2-yl}methyl 4-methylbenzenesulfonate (5.12 g, 11.8 mmole) in tetrahydrofuran (400 mL) was added 2.42 mL of 4% aqueous osmium tetroxide (0.39 mmole). After 0.5 hour, sodium periodate (12.6 g, 59.1 mmole) in water (100 mL) was added dropwise over a period of 1 hour. The heterogeneous solution was stirred under nitrogen at room temperature overnight. The mixture was diluted with water and extracted with ethyl acetate. The organic layer was washed with brine, dried over

magnesium sulfate, filtered and concentrated in vacuum to yield the (R)-enantiomer of the title compound as a light beige solid (4.80 g, 97%).

Elemental Analysis for: C₁₉H₁₉NO₈S • 0.2 H₂O

Calc'd: C, 53.69; H, 4.60; N, 3.30

5 Found: C, 53.47; H, 4.45; N, 3.23

INTERMEDIATE 10

{8-Hydroxy-7-[(methoxycarbonyl)amino]-2,3-dihydro-1,4-benzodioxin-2-yl}methyl 4-methylbenzenesulfonate

10

A solution of {(2R)-8-formyl-7-[(methoxycarbonyl)amino]-2,3-dihydro-1,4-benzodioxin-2-yl}methyl 4-methylbenzenesulfonate (8.46 g, 20.0 mmole) in methylene chloride (250 mL) was added dropwise to a solution of 57-86% m-chloroperoxybenzoic acid (11.5 g, 40-48 mmole) in methylene chloride (120 mL). The reaction was 15 stirred under nitrogen overnight. After dilution to 300 mL with methylene chloride, the solution was washed with saturated sodium aqueous sodium bicarbonate (2 x 200 mL) and with brine (100 mL), dried over magnesium sulfate, filtered and evaporated to dryness in vacuum. A H¹ NMR spectra of the crude product was taken and it was determined to be the intermediate formate ester. Hydrolysis was effected by stirring 20 in methanol over basic alumina for 15 hours. After filtration of the mixture and evaporation of the filtrate in vacuum, the residue was purified by column chromatography on silica gel with 20% hexane/methylene chloride to remove the impurities and methylene chloride to elute the product. Combination of the product fractions and concentration in vacuum gave the (R)-enantiomer of the title compound 25 as a dark green foam (5.41 g, 66%). ¹H (CDCl₃) doublet, 7.8 δ (2 H); doublet, 7.3 δ (2 H); doublet, 7.2 δ (1 H); broad singlet, 6.8 δ (1 H); doublet, 6.4 δ (1 H); broad singlet, 6.0 δ (1 H); multiplet, 4.4 δ (1 H); multiplet, 4.2 δ (3 H); multiplet, 4.0 δ (1 H); singlet, 3.8 δ (3 H); singlet, 2.4 δ (3 H).

INTERMEDIATE 11[2-Oxo-2,3,7,8-tetrahydro[1,4]dioxino[2,3-g][1,3]benzoxazol-8-yl]methyl 4-methylbenzenesulfonate

5 1,1'-Carbonyldiimidazole (6.45 g, 39.6 mmole) was added to a solution of
{(2R)-8-hydroxy-7-[(methoxycarbonyl)amino]-2,3-dihydro-1,4-benzodioxin-2-yl}-methyl
4-methylbenzenesulfonate (5.40 g, 13.2 mmole) in methylene chloride (400 mL), the
solution was refluxed for 4 hours under nitrogen. The solvent was then removed in
vacuum and was replaced with 2N aqueous HCl (150 mL). After the mixture had been
10 stirred for 0.5 hour at room temperature, a white solid precipitate, the (R)-enantiomer
of the title compound, was removed by filtration, and was dried under high vacuum
(5.0 g, >99%).

Elemental Analysis for: C₁₇H₁₅NO₇S • H₂O

Calc'd: C, 51.64; H, 4.33; N, 3.54

15 Found: C, 51.54; H, 4.10; N, 3.47

INTERMEDIATE 128-(Azidomethyl)-7,8-dihydro[1,4]dioxino[2,3-g][1,3]benzoxazol-2(3H)-one

20 Sodium azide (0.86 g, 13.2 mmole) was added to a solution of [(8R)-2-oxo-
2,3,7,8-tetrahydro[1,4]dioxino[2,3-g][1,3]benzoxazol-8-yl]methyl 4-methylbenzenesul-
fonate (5.0 g, 13 mmole) in dimethylformamide (250 mL). The solution was heated
at 70°C for 9 hours. The solvent was then removed in vacuum and replaced with 300
ml of methylene chloride. The mixture was washed with 300 mL portions of water
25 and saturated brine, dried over magnesium sulfate, filtered and evaporated in vacuum
to a yellow solid. The crude solid was column chromatographed on silica gel with 3%
methanol in methylene chloride to yield the (S)-enantiomer of the title compound as a
white solid (2.86 g, 86%).

Elemental Analysis for: C₁₀H₈N₄O₄

30 Calc'd: C, 48.39; H, 3.25; N, 22.57

Found: C, 48.77; H, 3.25; N, 22.12

EXAMPLE 18-Aminomethyl-7,8-dihydro-3H-1,6,9-trioxa-3-aza-cyclopenta[a]naphthalen-2-one

(8S)-8-(Azidomethyl)-7,8-dihydro[1,4]dioxino[2,3-g][1,3]benzoxazol-2(3H)-one
5 (2.86 g, 11.5 mmole) in methanol (60 mL) was treated for 24 hours on a Parr shaker with 60 psi of hydrogen in the presence of 0.43 g of 10% Pd/C and 3.0 mL of 4 N isopropanolic HCl. The catalyst was removed by filtration through celite and was washed with additional methanol. The filtrate was evaporated in vacuum to give 2.12 g (68%) of the (S)-enantiomer of the title compound as a beige solid, m.p. > 250°C.
10 Elemental Analysis for: C₁₀H₁₀N₂O₄ • HCl
Calc'd: C, 46.44; H, 4.29; N, 10.83
Found: C, 46.49; H, 4.11; N, 10.34

EXAMPLE 2

15 8-(Benzylamino-methyl)-7,8-dihydro-3H-1,6,9-trioxa-3-aza-
cyclopenta[a]naphthalen-2-one

(8S)-8-Aminomethyl-7,8-dihydro-3H-1,6,9-trioxa-3-aza-cyclopenta[a]-naphthalen-2-one hydrochloride (0.49 g, 1.8 mmole), benzyl bromide (0.20 mL, 1.8 mmole) and 0.31 mL (1.8 mmole) of N,N-diisopropylethylamine were combined in 20 mL DMSO and heated at 50°C under nitrogen for 6 hours. After completion, the reaction was cooled to room temperature and partitioned between 400 mL each of ethyl acetate and saturated aqueous sodium bicarbonate. The organic phase was removed and washed with brine, dried over magnesium sulfate and concentrated in vacuum. The crude residue was column chromatographed on silica gel using first methylene chloride, then 1% methanol in methylene chloride to elute the dialkylated product and finally 3% methanol in methylene chloride to elute the monoalkylated product (0.16 g, 28%). The latter was recrystallized from ethanol with the addition of a solution of fumaric acid (0.065 g) in hot ethanol to give 0.06 g of the (S)-enantiomer of the title compound as an off-white solid hemifumarate, one-quarter hydrate, m.p. 220°C.

Elemental Analysis for: C₁₇H₁₆N₂O₄ • 0.50 C₄H₄O₄ • 0.25 H₂O
Calc'd: C, 60.88; H, 4.98; N, 7.47
Found: C, 61.12; H, 4.73; N, 7.36

EXAMPLE 38-[(Dibenzylamino)-methyl]-7,8-dihydro-3H-1,6,9-trioxa-3-aza-
cyclopenta[a]naphthalen-2-one

5

Combination of the column chromatography fractions from example 2 which were obtained by elution with 1% methanol in methylene chloride and which contained dialkylated product and concentration of those fractions in vacuum led to the isolation of 0.060 g of the (S)-enantiomer of the title compound as a white crystalline solid, m.p.

10 210°C.

Elemental Analysis for: C₂₄H₂₂N₂O₄ • 0.50 H₂OCalc'd: C, 70.06; H, 5.63; N, 6.81Found: C, 70.26; H, 5.33; N, 6.74

15

EXAMPLE 48-[(4-Phenyl-butylamino)-methyl]-7,8-dihydro-3H-1,6,9-trioxa-3-aza-
cyclopenta[a]naphthalen-2-one

(8S)-8-Aminomethyl-7,8-dihydro-3H-1,6,9-trioxa-3-aza-cyclopenta[a]-naphthalen-2-one hydrochloride (0.40 g, 1.5 mmole), 1-(4-chlorobutyl)benzene (0.24 g, 1.5 mmole), 0.50 mL (2.9 mmole) of N,N-diisopropylethylamine and sodium iodide (0.11 g, 0.73 mmole) were combined in 25 mL DMSO and heated at 70°C for 6 hours under nitrogen. After completion, the reaction was cooled to room temperature and partitioned between 200 mL each of ethyl acetate and saturated aqueous sodium bicarbonate. The organic phase was washed with brine, dried over magnesium sulfate, filtered and concentrated in vacuum. The crude residue was column chromatographed on silica gel using 5% methanol in methylene chloride to elute the desired product (0.18 g, 52%). The crude free base was crystallized from ethanol with the addition of a solution of fumaric acid (0.06 g) in hot ethanol to give 0.022 g of the (S)-enantiomer of the title compound as a beige solid fumarate, three-quarters hydrate, m.p. 215-218°C.

Elemental Analysis for: C₂₀H₂₂N₂O₄ • 1.00 C₄H₄O₄ • 0.75 H₂OCalc'd: C, 59.56; H, 5.73; N, 5.79Found: C, 59.50; H, 5.25; N, 5.71

EXAMPLE 58-[4-(1H-Indol-3-yl)-3,6-dihydro-2H-pyridin-1-ylmethyl]-7,8-dihydro-3H-1,6,9-trioxa-3-aza-cyclopenta[a]naphthalen-2-one

5

0.85 g (2.08 mmole) of {(2R)-8-hydroxy-7-[(methoxycarbonyl)amino]-2,3-dihydro-1,4-benzodioxin-2-yl}methyl 4-methylbenzenesulfonate and 1.13 g (5.70 mmole) of 3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole were combined in DMSO (40 mL) and heated at 60°C under nitrogen for 6 hours. After completion, the reaction was cooled to room temperature and partitioned between 300 mL each of ethyl acetate and saturated aqueous sodium bicarbonate. The organic phase was washed with brine, dried over magnesium sulfate, filtered and concentrated in vacuum to a viscous oil. The crude oil was dissolved in methylene chloride and was heated at reflux in the presence of carbonyl diimidazole (1.02 g) for 4 hours. The reaction was allowed to cool to room temperature and the solvent was removed in vacuum. The residue was column chromatographed on silica gel using first 20% hexane/methylene chloride, then methylene chloride and finally 2% methanol/methylene chloride as eluant. The product fractions were combined and concentrated in vacuum to give 0.080 g of the (S)-enantiomer of the title compound as a light yellow solid, m.p. 202°C.


Elemental Analysis for: C₂₃H₂₁N₃O₄ • 0.50 H₂O
Calc'd: C, 66.98; H, 5.38; N, 10.19
Found: C, 66.73; H, 5.33; N, 9.96

CLAIMS

What is claimed is:

5

(1) A compound of formula I




wherein

R¹ is hydrogen, halo, cyano, carboxamido, carboalkoxy of two to six carbon atoms, trifluoromethyl, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, alkanoyloxy of 2 to 6 carbon atoms, amino, mono- or di-alkylamino in which each alkyl group has 1 to 6 carbon atoms, alkanamido of 2 to 6 carbon atoms, or alkanesulfonamido of 1 to 6 carbon atoms;

10

Z is defined by N R²-(CH₂)ₙ-Y,

15



wherein

20

Y is hydrogen, hydroxy, cycloalkyl of 3 to 15 carbon atoms or phenyl, substituted phenyl, phenoxy, substituted phenoxy, naphthyl, substituted naphthyl, naphthyloxy, substituted naphthyloxy, heteroaryl, substituted heteroaryl, heteroaryloxy or substituted heteroaryloxy, wherein the heteroaryl or the heteroaryl group of heteroaryloxy is selected from thiophene, furan, pyridine, indole, chroman, coumarin, carbostyryl, and quinoline;

R² is hydrogen, benzyl or alkyl of 1 to 6 carbon atoms;


n is an integer from 0 to 6;

25

R³ is hydrogen, alkyl of 1 to 6 carbon atoms, phenyl, substituted phenyl, ω-phenylalkyl, substituted ω-phenylalkyl, ω-diphenylalkyl, substituted ω-diphenylalkyl, wherein the alkyl chain contains 1 to 4 carbon atoms, indole,

substituted indole, indazole, substituted indazole, pyridine, substituted pyridine, pyrimidine, substituted pyrimidine, quinoline, substituted quinoline, benzoisothiazole, substituted benzoisothiazole, benzisoxazole, or substituted benzisoxazole;

5 R⁴ is hydrogen, hydroxy, cyano or carboxamido;
 R⁵ is hydrogen, 1-benzimidazol-2-one, benzoisothiazole, or benzisoxazole, each optionally substituted, or -Q-Ar;
 Q is C=O, CHOH, or (CH₂)_m,
 m is an integer from 0 to 4;
 10 Ar is phenyl or indole, each optionally substituted; or
 R⁴ and R⁵, taken together with the carbon atom to which they are attached, form



R⁶ is hydrogen; and
 15 R⁷ is phenyl, indole, naphthyl, thiophene, benzoisothiazole, or benzisoxazole, each optionally substituted; or
 R⁶ and R⁷, taken together with the carbon atoms to which they are attached form phenyl or substituted phenyl;
 R⁸ is hydrogen or alkyl of 1 to 6 carbon atoms; and
 20 R⁹, R¹⁰ and R¹¹ are, independently hydrogen, halo, cyano, carboxamido, carboalkoxy of two to six carbon atoms, trifluoromethyl, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, alkanoyloxy of 2 to 6 carbon atoms, amino, mono- or di-alkylamino in which each alkyl group has 1 to 6 carbon atoms, alkanamido of 2 to 6 carbon atoms, or alkanesulfonamido of 1 to 6 carbon atoms; or a pharmaceutically acceptable salt thereof.

(2) A compound according to Claim 1 wherein R¹ is hydrogen, methoxy or halogen.

(3) A compound according to Claim 1 or Claim 2 wherein Z is NR²-(CH₂)_n-Y.

5 (4) A compound according to Claims or Claim 2 wherein R² is hydrogen.

(5) A compound according to Claim 1 or Claim 2 wherein R³ is phenyl, indole, indazole, pyridine, pyrimidine, quinoline, benzoisothiazole, or benzisoxazole, each 10 optionally substituted.

(6) A compound according to Claim 1 or Claim 2 wherein R⁴ is hydrogen or hydroxy.

15 (7) A compound according to any one of Claims 1, 2 and Claim 6 wherein R⁵ is 1-benzimidazol-2-one, benzoisothiazole, benzisoxazole, each optionally substituted or – Q-Ar.


(8) A compound according to Claim 7 wherein Q is C=O or (CH₂)_m.

20 (9) A compound according to Claim 1 or Claim 2 wherein R⁶ is hydrogen.

(10) A compound according to any one of Claims 1, 2 and 9 wherein R⁷ is phenyl, indole, benzoisothiazole, or benzisoxazole each optionally substituted.


25 (11) A compound according to Claim 1 or Claim 2 wherein R⁶ and R⁷ taken together form phenyl or substituted phenyl.

(12) A compound of Claim 1 wherein R¹ is hydrogen, methoxy, or halogen, Z is NR²-(CH₂)_n-Y and R² is hydrogen.



(13) A compound of Claim 1 wherein Z is , and R³ is phenyl, indole, indazole, pyridine, pyrimidine, quinoline, benzoisothiazole, or benzisoxazole, each optionally substituted.


5 (14) A compound of Claim 3 wherein R¹ is hydrogen, methoxy or halogen.



(15) A compound of Claim 1 wherein Z is , R⁴ is hydrogen or hydroxy and R⁵ is 1-benzimidazol-2-one, benzoisothiazole, or benzisoxazole, each optionally substituted.

10


(16) A compound of Claim 15 wherein R¹ is hydrogen, methoxy or halogen.



(17) A compound of Claim 1 wherein Z is , R⁴ is hydrogen or hydroxy, R⁵ is -Q-Ar, Q is C=O or (CH₂)_m, m is 0 to 4, and Ar is phenyl or indole, each optionally substituted.


15

(18) A compound of Claim 17 wherein R¹ is hydrogen, methoxy or halogen, Q is C=O, and Ar is phenyl or substituted phenyl.



20 (19) A compound of Claim 1 wherein Z is , R⁶ is hydrogen and R⁷ is phenyl, indole, benzoisothiazole, or benzisoxazole, each optionally substituted.

(20) A compound of Claim 19 wherein R¹ is hydrogen, methoxy or halogen.



(21) A compound of Claim 1 wherein Z is , R⁶ and R⁷, taken together with the carbon atoms to which they are attached form phenyl or substituted phenyl.

5 (22) A compound of Claim 21 wherein R¹ is hydrogen, methoxy or halogen.

(23) The compound of Claim 1 which is 8-aminomethyl-7,8-dihydro-3H-1,6,9-trioxa-3-aza-cyclopenta[a]naphthalen-2-one or a pharmaceutically acceptable salt thereof.

10 (24) The compound of Claim 1 which is 8-(benzylamino-methyl)-7,8-dihydro-3H-1,6,9-trioxa-3-aza-cyclopenta[a]naphthalen-2-one or a pharmaceutically acceptable salt thereof.

15 (25) The compound of Claim 1 which is 8-[(dibenzylamino)-methyl]-7,8-dihydro-3H-1,6,9-trioxa-3-aza-cyclopenta[a]naphthalen-2-one or a pharmaceutically acceptable salt thereof.

20 (26) The compound of Claim 1 which is 8-[(4-phenyl-butylamino)-methyl]-7,8-dihydro-3H-1,6,9-trioxa-3-aza-cyclopenta[a]naphthalen-2-one or a pharmaceutically acceptable salt thereof.

(27) The compound of Claim 1 which is 8-[4-(1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-ylmethyl]-7,8-dihydro-3H-1,6,9-trioxa-3-aza-cyclopenta[a]naphthalen-2-one or a pharmaceutically acceptable salt thereof.

25 (28) A method of treating a subject suffering from a condition selected from schizophrenia, schizoaffective disorder, bipolar disorder, Parkinson's disease, L-DOPA induced psychoses or dyskinesias, Tourette's syndrome or hyperprolactinemia which comprises providing to the subject suffering from said condition, a therapeutically effective amount of a compound of formula I as claimed in any one of claims 1 to 27.


(29) A pharmaceutical composition comprising a compound of formula I as claimed in any one of Claims 1 to 27 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.

5

(30) A process for preparing a compound according to claim 1 which comprises one of the following:

a) reacting a compound of formula

10



wherein R¹ is as defined above and X is a leaving group, eg halogen or an organic sulphonyloxy group such as an alkyl- or aryl- sulphonyloxy group, eg -OTs;

15 with a compound of formula (III):




wherein Z is as defined in Claim 1 to give a compound of formula (I);

20


or

b) reacting a compound of formula (IV)

25



wherein R¹ and R² are defined above; with a compound of formula (III):



5 wherein Y is as defined in Claim 1 and X is a leaving group, e.g. halogen, to give a compound of formula (I);

c) converting a basic compound of formula (I) to a pharmaceutically acceptable acid addition salt thereof;

10 or

d) resolving an isomeric mixture of compounds of formula (I) to isolate an enantiomer of a compound of formula (I) or a pharmaceutically acceptable salt thereof,

15 or

e) reacting a compound of formula (II) as defined above with an alkali metal azide followed by reduction to give a compound of formula (I) wherein Z is NH₂,

20 or

f) alkylating a compound of formula (I) wherein Z is NH₂ with an alkylating agent of formula XR² wherein X is as defined herein and R² is benzyl or alkyl of 1 to 6 carbon atoms to give a corresponding compound of formula (I) wherein Z is NHR².

30

INTERNATIONAL SEARCH REPORT

Inte ~~n~~ International Application No
PCT/US 02/13419

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07D498/04 A61K31/424 A61P25/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 00 29397 A (FEENSTRA ROELOF W ; DUPHAR INT RES (NL); LONG STEPHEN K (NL); MOS J) 25 May 2000 (2000-05-25) abstract	1,28,29
A	WO 97 32871 A (TAKEDA CHEMICAL INDUSTRIES LTD) 12 September 1997 (1997-09-12) abstract	1,28,29



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority, claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

18 September 2002

Date of mailing of the international search report

26/09/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Palentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Diederens, J

INTERNATIONAL SEARCH REPORT

national application No.
PCT/US 02/13419

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:

Although claim 28 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of Invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No	
PCT/US 02/13419	

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0029397	A	25-05-2000	AU 1270900 A BR 9915293 A CZ 20011657 A3 WO 0029397 A1 EP 1131308 A1 NO 20012339 A PL 347635 A1 SK 6492001 A3	05-06-2000 07-08-2001 17-10-2001 25-05-2000 12-09-2001 11-05-2001 22-04-2002 08-10-2001
WO 9732871	A	12-09-1997	AT 219071 T AU 706610 B2 AU 2231897 A CA 2241666 A1 CN 1212691 A CZ 9802775 A3 DE 69713294 D1 EP 0885210 A1 HU 9900616 A2 JP 2884153 B2 JP 10287665 A WO 9732871 A1 JP 11152281 A NO 983970 A NZ 330656 A PL 328726 A1 SK 115098 A3 US 6218429 B1 US 6034239 A	15-06-2002 17-06-1999 22-09-1997 12-09-1997 31-03-1999 16-12-1998 18-07-2002 23-12-1998 28-06-1999 19-04-1999 27-10-1998 12-09-1997 08-06-1999 28-08-1998 29-06-1999 15-02-1999 10-03-1999 17-04-2001 07-03-2000